An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Sierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Sierra Oncology, Inc. (Nasdaq: SRRA) announced that underwriters fully exercised their option to purchase an additional 750,000 shares at $27.00 each, raising approximately $155.3 million in gross proceeds. The offering closed on February 3, 2022. The funds will support the commercialization of momelotinib, clinical development of other product candidates, and general corporate purposes. Jefferies and Cantor acted as joint book-running managers for the offering. This follows a previously effective shelf registration statement filed with the SEC.
Positive
Raised approximately $155.3 million in gross proceeds from the offering.
Funding supports potential commercialization of momelotinib and other product candidates.
Negative
None.
SAN MATEO, Calif.--(BUSINESS WIRE)--
Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced that the underwriters of its previously announced underwritten public offering exercised in full their option to purchase 750,000 additional shares of common stock at a price of $27.00 per share, before deducting underwriting discounts and commissions. With this exercise, the aggregate gross proceeds to Sierra Oncology from the offering were approximately $155.3 million, before deducting underwriting discounts and commissions and other offering expenses. The offering of the additional 750,000 shares closed on February 3, 2022. Sierra Oncology intends to use the net proceeds of the offering to prepare for potential commercialization of momelotinib, clinical development of its other product candidates, research, clinical and process development and manufacturing of its product candidates, working capital, and capital expenditures and other general corporate purposes.
Jefferies and Cantor acted as the joint book-running managers and representatives of the underwriters for the offering. LifeSci Capital, Oppenheimer & Co. and H.C. Wainwright & Co. acted as lead managers for the offering.
A shelf registration statement on Form S-3 relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on November 5, 2021 and declared effective by the SEC on November 12, 2021. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@jefferies.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, New York, New York 10022, or by e-mail at prospectus@cantor.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Sierra Oncology
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Our team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Together we are transforming promise into patient impact.
What is the recent public offering by Sierra Oncology (SRRA)?
Sierra Oncology announced a public offering where underwriters exercised their option to purchase 750,000 additional shares at $27.00 each, raising approximately $155.3 million.
When did Sierra Oncology close its additional share offering?
The additional share offering closed on February 3, 2022.
How will Sierra Oncology use the proceeds from the offering?
The proceeds will be used for the commercialization of momelotinib, clinical development of other product candidates, and general corporate purposes.
Who managed the public offering for Sierra Oncology?
Jefferies and Cantor acted as the joint book-running managers for the offering.
